Company Overview: Y-mAbs Therapeutics, Inc.

What the Company Does:
Y-mAbs Therapeutics, Inc. is a biotechnology company focused on developing and commercializing radiopharmaceuticals, specifically diagnostic and therapeutic agents based on nuclear medicine. The company aims to harness radioactive compounds for medical applications, primarily in cancer treatment and diagnosis.

Key Details:

• Industry: Biotechnology, specializing in radiopharmaceuticals and oncology treatments.
• Company Focus: Development and commercialization of laboratory-based radiopharmaceutical diagnostics and therapies, including high-risk neuroblastoma treatment (e.g., Danyelza).
• Employees: As of April 14, 2025, the number of outstanding shares is approximately 45,276,915, but the exact number of employees is not provided.

Financials & Market Data:

• Market Capitalization: As of June 30, 2024, the company's market value of common stock held by non-affiliates was approximately $450 million.
• Revenue & Income: The provided document does not specify total revenue, net income, or detailed financial figures. It primarily contains corporate governance, executive compensation, and stock ownership information.

Customers & Business Operations:

• The document does not specify the exact number of customers.
• Focus appears to be on clinical development, regulatory approvals, and strategic partnerships rather than on specific customer counts.

Additional Details:

• Stock Listing: Listed on The Nasdaq Global Select Market under the symbol YMAB.
• Stockholders: Significant ownership held by institutional investors and insiders, including entities affiliated with WG Biotech ApS, Paradigm BioCapital, HBM Healthcare Investments, and BlackRock.
• Company Initiatives: Developing and commercializing radiopharmaceuticals, including progressing clinical trials, establishing strategic partnerships, and filing regulatory applications (e.g., IND filings with the FDA).

Summary:
Y-mAbs Therapeutics, Inc. is a biotech firm focused on radiopharmaceuticals for cancer diagnosis and treatment, with a market cap of around $450 million, but specific details about revenue, net income, and customer counts are not provided in the document.